Implementation of Early Detection and Early Intervention Service Delivery in Infants at Risk for Cerebral Palsy to Promote Infants' Psychomotor Development and Maternal Health
NCT ID: NCT04622787
Last Updated: 2022-09-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
500 participants
OBSERVATIONAL
2021-06-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessing Intellectual and Motor Outcomes in High-risk Infants
NCT06857539
Early Identification of Infants at Risk of Cerebral Palsy
NCT03211533
Infants With Agenesis of the Corpus Callosum
NCT02267161
Gastro-oesophageal Reflux and NeuroDisability (Cerebral Palsy) in CHILDren
NCT04293107
Neuromotor Development and Motor Related Health Care in Children with a High Risk Neonatal Period
NCT06645717
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary objectives A1 To optimize the context-specific health programs for early detection of CP through the implementation of a tailored multifaceted knowledge translation strategy, in \>500 infants with CP from Tuscany (Italy); Denmark; Netherlands, Georgia, Sri Lanka, and rural/ remote Australia (QLD, WA).
The investigators will also evaluate health care resource usage following the implementation of our translation strategy compared with a two-year period prior to the implementation- e.g. costs of early detection and targeted surveillance, targeting infants with CP (costs and consequences/outcomes of surveillance and intervention).
H1 Our hypothesis is that, compared with usual care, implementation of our translation strategy will increase the proportion of children that receive a diagnosis of CP \<6 months of age from \~25% to \>60%, as measured by CP Registers. Additional costs of screening and surveillance in our translation strategy will be off-set by targeting the highest risk babies earlier. Health care costs and usage will be focused on the most at-risk group, leading to improved outcomes across all children (costs/consequences analysis).
A2 To optimize the context-specific health programs for early surveillance of associated impairments and functional limitations of infants with CP, thereby fostering individualised (needs-based patient specific) early intervention and preventing secondary complications (e.g. hip dislocation, feeding disorders). The investigators will evaluate the early developmental trajectory of CP in infants aged 0-2 years and parental mental health to inform early intervention and surveillance needs to improve prediction of outcomes. The investigators will also compare the rates of hip displacement at 2 years following the implementation of our translation strategy compared with usual care (i.e. proportion of children with migration percentage \>30%).
H2 Our hypothesis is that the natural history of CP in infants aged 0-2 years will differ according to motor severity, with different trajectories identified as early as 6 months' corrected age. The investigators also predict a reduction in the rate of hip displacement from 33% in current practice to \<10% following the implementation of our translation strategy (consistent with Scandinavian screening programs).
A3 To optimize the context-specific health programs for early intervention in infants with CP, thereby improving the outcomes of both the infant and the caregivers. In Low- and Middle-Income Countries (LMIC) and hard-to-reach populations the investigators will also implement a community-based, parent delivered early intervention program for infants at high risk of CP (LEAP-CP).
H3 Our hypothesis is that infants with CP who receive the multi-domain intervention will have better motor development (Peabody DMS), social- emotional development on the Infant-Toddler Social Emotional Assessment (ITSEA), cognitive development (Bayley Scale of Infant Development (BSID III)) compared to infants receiving care as usual. Caregivers who receive the multi-domain intervention will have reduced scores on the Depression, Anxiety and Stress Scale compared to caregivers receiving care as usual.
Based on the aims listed above, there will be 3 parallel studies within the protocol:
A: Healthcare Providers Observational Study B: Infant Prospective Observational study C: Infant wait-list Randomised Controlled Trial of LEAP-CP, a home - based early intervention (Georgia, Sri-Lanka and remote Australia only, RCT (randomized controlled trial) registered separately with ANZCTR)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tuscany, Italy
Infants at risk of Cerebral Palsy in Tuscany, Italy
No interventions assigned to this group
Infants at risk of Cerebral Palsy in Georgia
Infants at risk of Cerebral Palsy in Georgia
No interventions assigned to this group
Sri-Lanka
Infants at risk of Cerebral Palsy in Sri-Lanka
No interventions assigned to this group
Denmark
Infants at risk of Cerebral Palsy in Denmark
No interventions assigned to this group
Infants at risk of Cerebral Palsy in the Netherlands
the Netherlands
No interventions assigned to this group
remote Queensland, Australia
Infants at risk of Cerebral Palsy in remote Queensland, Australia
No interventions assigned to this group
Medical professionals
Medical/healthcare providers from all involved geographic locations that work with infants at risk or with diagnosis of cerebral palsy will be provided opportunities for the participation in face-to-face and/or e-learning platform trainings on the the international early detection guidelines.
Knowledge translation
A. Healthcare Providers Observational Study - measure of the effectiveness of the International Guidelines training courses (face to face and online) delivered to medical professionals (involves all clinical partners).
The International Guidelines training courses on the evidence-based principles of Early Detection (ED), Early surveillance (ES), and Early intervention (EI) will be delivered to healthcare providers.
Face-to-face professional trainings will be set up at each Consortium partner location. E-learning platform will allow for training and follow-up resources will be available to clinicians in all languages that are spoken/written in the locations of the Consortium partners.
Clinicians will be assessed on their knowledge and standard clinical practices in survey format before trainings and after the trainings.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Knowledge translation
A. Healthcare Providers Observational Study - measure of the effectiveness of the International Guidelines training courses (face to face and online) delivered to medical professionals (involves all clinical partners).
The International Guidelines training courses on the evidence-based principles of Early Detection (ED), Early surveillance (ES), and Early intervention (EI) will be delivered to healthcare providers.
Face-to-face professional trainings will be set up at each Consortium partner location. E-learning platform will allow for training and follow-up resources will be available to clinicians in all languages that are spoken/written in the locations of the Consortium partners.
Clinicians will be assessed on their knowledge and standard clinical practices in survey format before trainings and after the trainings.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Works with infants at risk or with diagnosis of cerebral palsy
* Practices in Georgia, Sri-Lanka, The Netherlands, Denmark, Remote Queensland region of Australia, Tuscan region of Italy,
* Extremely preterm
* Extremely low birthweight
* Neonatal encephalopathy
* Stroke
* Abnormal General Movements with abnormal brain neuroimaging
* Abnormal General Movements with abnormal Neurological Evaluation
* Abnormal brain neuroimaging with abnormal Neurological Evaluation
Exclusion Criteria
* Located (practicing) outside of study country locations
Infant and family observational study:
* Lethal abnormalities
* congenital conditions not associated with cerebral palsy (e.g. Down's Syndrome)
* complex medical conditions requiring acute medical care
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Commission
OTHER
National Health and Medical Research Council, Australia
OTHER
University of Pisa
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrea Guzzetta
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitá di Pisa
Pisa, PI, Italy
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
The General Data Protection Regulation (GDPR)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
848201
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
BornTogether
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.